Evotec SE partners with pharmaceutical and biotechnology companies to discover and develop new drugs. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 0.7× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 75% of them.
Analysts' average target sits 73% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $115.4M against $878.6M in annual sales. And on top of that, sales fell from the year before.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 16/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 22/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, EVO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EVO has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.